Jobs / United States / Glaxosmithkline LLC
Global Medical Director - Multiple Myeloma, Oncology
Glaxosmithkline LLC · 🇺🇸 Home Worker - USA
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Glaxosmithkline LLC paid sponsored hires in similar roles1 certified filing for “Sr Manager - Oncology Commercial Analytics, Multiple Myeloma” (Data Scientists) in PA: $135k–$135k, median $135k. Most were filed at wage level III (100%) — 3 lottery entries, ≈46% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Glaxosmithkline LLC
The US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Glaxosmithkline LLC →
About the role
Position Summary The Global Medical Affairs Director, Oncology (Multiple Myeloma) role provides strategic global medical affairs leadership for an assigned oncology asset or portfolio. The role holder will set and deliver the long-term disease and medicine strategy, lead integrated global medical plans, and shape external clinical practice to help GSK get Ahead of Disease Together and positively impact patient and population health outcomes in oncology. They will operate in a complex matrix, partnering closely with commercial, clinical development, value & evidence, and country medical teams to drive launch and lifecycle success for oncology assets. The role is within a team reporting to the Vice President, Global Medical Lead (GML) for the specific asset/portfolio. Strategic accountability for all activities aligned to the asset strategy sits with the GML, with implementation and leadership of designated projects led by the Global Medical Affairs Director. This role will provide YOU the opportunity to lead key activities to progress YOUR career. These responsibilities include some of the following: Medical Business Leadership • Serve as a key medical business leader for the assigned oncology asset/portfolio, accountable to the Global Medical Lead for strategy and execution. • Represent the Chief Patient organisation as a medical business leader, applying deep oncology scientific expertise from early development through lifecycle management to improve patient and population outcomes. • Lead/support development of the global disease and asset strategy, integrating scientific, clinical, and market insights to understand unmet needs and guide evidence priorities, communication narratives, product positioning, and evidence generation strategy in oncology. • Act as a primary interface with senior internal leaders and external stakeholders (clinical experts, advocacy groups, regulators, payors) to shape disease understanding and treatment paradigms in oncology. • Think globally while deeply understanding priority LOC needs via extensive partnership with country medical and cross-functional teams; translate local insights into global plans and deliverables. • Lead Global Medical Operational Planning for the asset, ensuring plans are externally-focused, insight-driven and delivered on time and on budget across indications and geographies. Evidence Generation & Data Strategy • Partner across R&D, Real-World Evidence (RWE), Health Outcomes, Global Product Strategy and country teams to identify and prioritize oncology evidence generation needs to close data gaps, support clinical and economic differentiation, and optimize clinical care. • Develop scientific questions based on prioritized data gaps and work closely with Data Generation leads to shape Phase 3b/4 and value/evidence plans for the asset. • Be accountable for timely review and approval of Phase 3b/4 and value evidence/health outcomes studies within remit, ensuring scientific rigor and strategic alignment. • Review investigator-sponsored study proposals (ISS) for strategic alignment and scientific merit in liaison with R&D, Safety, Biostatistics and other experts. Scientific Communications & Publications • Partner with Scientific Communications Leads and Integrated Medical Communications teams to align scientific narratives, publication strategy, and engagement tactics to the global oncology medical strategy. • Define key scientific messages and provide oversight for integrated scientific communication plans (congress strategy, medical education, digital engagement, omnichannel content) for the asset. • Lead development and communication of newsflow for the asset (e.g., data milestones, congress plans, publication timelines) on a regular basis. • Drive excellence